Candel Therapeutics, Inc

CADLNASDAQ · Biological Products, (No Diagnostic Substances)

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

76.1M

on 2026-06-30, from 29.3M on 2024-03-31 10-Q ↗

a raise that quarter, at its price

Newest

$50.0M

S-3 of 2025-08-14. 1 prospectus supplement filed under it since. S-3 ↗

$50.0M

Jefferies, agreement of 2025-08-14. No at-the-market sales statement read from a 10-Q or 10-K. S-3 ↗

Warrants

The 10-Q filed 2026-08-13 is not read yet.

Cash

14.4 quarters

$201.6M on 2026-06-30 ÷ $14.0M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised
Date	What	Shares	Price	Gross	Filing
2026-02-19	Public offering	18,348,624	$5.45	$100.0M	424B5 ↗
2025-06-23	Registered direct offering	3,221,395	$4.67	$15.0M	424B5 ↗
2024-12-13	Public offering incl. 3.33M pre-funded	13,333,334	$6.00	$80.0M	424B5 ↗

Also on file: up to $130.0M term loan agreed 2025-10-14 8-K ↗